Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + clonidine
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intrathecal, Epidural
01
Overview
A combination of bupivacaine, an amide local anesthetic, and clonidine, an alpha-2 adrenergic agonist. This combination is used for spinal anesthesia, caudal blocks, and other regional anesthetic procedures. The addition of clonidine to bupivacaine increases the spread of analgesia, prolongs the duration of sensory block, and decreases postoperative pain requirements compared to bupivacaine alone.
- Other names
- Cervical Sympathetic Block (bupivicaine, clonidine)
02
Targets
ADRA2A (α2A)NaV (Voltage-gated sodium channels)PTGER1 (Prostaglandin E Receptor 1)
Beyond the preview
Go deeper on bupivacaine + clonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + clonidine.